You are here: Home » Reuters » News
Business Standard

AstraZeneca tops sales forecasts, stays calm on Brexit


(Reuters) - British drugmaker AstraZeneca Plc beat expectations for product sales in the fourth quarter and forecast a second consecutive year of growth, driven by gains in emerging markets including China and demand for its new cancer medicines. The company was also the latest pharma major to say that it had made extensive preparations for Brexit, adding it assumed that Britain's departure from the European Union would be "orderly" even if it leaves without a deal with Brussels. Much of AstraZeneca's push to build a strong shelf of newer drugs and turn around a slump in sales is riding on ...

This article is no longer available in our repository.

There could be multiple reasons for this.

First Published: Thu, February 14 2019. 13:03 IST